Type 2 Diabetes Clinical Trials

425 recruiting

Understanding Type 2 Diabetes Clinical Trials

Semaglutide (Ozempic, Wegovy), which emerged from clinical trials as a GLP-1 receptor agonist, has not only improved blood sugar control but also demonstrated significant cardiovascular and weight-loss benefits that have reshaped how type 2 diabetes is managed. SGLT2 inhibitors like empagliflozin (Jardiance), also validated through landmark trials, have proven to protect the heart and kidneys in addition to lowering glucose. Clinical trials continue to push the boundaries of diabetes care, testing next-generation therapies that aim to achieve remission, protect organs, and reduce the daily burden of managing this chronic condition.

Why Consider a Clinical Trial?

Despite significant progress, many people with type 2 diabetes still struggle to achieve and maintain optimal blood sugar control, and complications affecting the heart, kidneys, eyes, and nerves remain common. Clinical trials offer access to next-generation GLP-1 and dual GIP/GLP-1 agonists, oral insulin formulations, cell-based therapies, and precision medicine approaches that could provide better results with fewer side effects than current treatments. Trials are also studying whether aggressive early treatment can put type 2 diabetes into sustained remission — meaning normal blood sugar levels without medication. For patients at high risk of developing diabetes, prevention trials test whether medications, dietary interventions, or digital health tools can stop or delay the disease from ever developing. Participation typically includes comprehensive metabolic monitoring that goes well beyond routine diabetes care.

Frequently Asked Questions

Common questions about Type 2 Diabetes clinical trials

It depends on the trial. Some studies allow you to continue your current medications and add the investigational treatment on top. Others may require you to stop or adjust certain medications to accurately assess the new therapy's effect. The study team will explain medication requirements during screening and ensure any changes are made safely.

The investigational treatment and research-related tests are typically covered by the trial sponsor at no cost to you. Routine care costs are usually billed to your insurance. Some trials offer stipends or reimbursement for travel and parking. Ask the study coordinator about financial details before enrolling.

Visit frequency varies by trial but is commonly every 4 to 12 weeks during active treatment. Some visits involve blood draws and physical exams, while others may be shorter check-ins. Many modern diabetes trials incorporate telehealth options to reduce the number of in-person visits required.

Many diabetes trials accept participants with common comorbidities, and some specifically study diabetes treatments in patients with cardiovascular or kidney disease. However, each trial has its own eligibility criteria. Having additional health conditions does not automatically disqualify you, and some trials are designed specifically for these populations.

When the trial ends, your study team will work with your regular doctor to transition you back to standard care. If the investigational treatment was effective, you may be eligible for an extension study that provides continued access. Your study team will ensure you have an appropriate treatment plan in place before discharge.

Showing 120 of 425 trials

Recruiting
Phase 2

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

Type 2 DiabetesCortisol Excess
Sparrow Pharmaceuticals1,500 enrolled46 locationsNCT07296484
Recruiting
Not Applicable

Using Continuous Glucose Monitoring to Quantify the Effects of NOURISH's Culturally Modified Meals on Asian Americans With Type 2 Diabetes

Type 2 Diabetes Mellitus (T2DM)Type 2 Diabetes
Stanford University30 enrolled1 locationNCT06836479
Recruiting
Not Applicable

Improving Kidney Care in Type 2 Diabetes: A Study of Pharmacist Prescribing Versus Usual Care

Chronic Kidney DiseaseType 2 DiabetesDiabetic Kidney Disease
Nova Scotia Health Authority120 enrolled1 locationNCT07169422
Recruiting
Phase 1

A Study of REGEND003 on Patients With Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD)

Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD)
Regend Therapeutics15 enrolled1 locationNCT07275788
Recruiting

An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea

Chronic Kidney DiseaseType 2 Diabetes Mellitus
Bayer500 enrolled1 locationNCT07232537
Recruiting
Phase 3

Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)

ObesityOverweight (Without Type 2 Diabetes) With Weight-related Comorbidities
Hudson Biotech2,539 enrolled1 locationNCT07481747
Recruiting
Phase 3

A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes

Obesity or OverweightType 2 Diabetes Mellitus
Hoffmann-La Roche1,600 enrolled3 locationsNCT07351058
Recruiting
Not Applicable

Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)

Type 2 Diabetes Mellitus (T2DM)Chronic Kidney Disease(CKD)Type 2 DM
Duke University420 enrolled6 locationsNCT06906640
Recruiting
Not Applicable

High Intensity Interval Training and Insulin Sensitivity in Type 2 Diabetes

Insulin Sensitivity/ResistanceType 2 DiabetesLifestyle-related Condition
Finis Terrae University36 enrolled1 locationNCT06688461
Recruiting
Phase 4

iGlarLixi CGM Study in Chinese T2D Individuals After OADs

Type 2 Diabetes (T2D)
Sanofi678 enrolled1 locationNCT06671587
Recruiting
Not Applicable

Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)

Type 2 Diabetes Mellitus (T2DM)Chronic Kidney Disease(CKD)Type 2 DM
Duke University750 enrolled6 locationsNCT06906627
Recruiting
Not Applicable

A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes

Prediabetes / Type 2 Diabetes
QuickSilver Scientific90 enrolled1 locationNCT07195994
Recruiting
Not Applicable

Exercise and Protein Efficiency in T2D

Type 2 DiabetesControl Condition
University of Illinois at Urbana-Champaign30 enrolled1 locationNCT07477067
Recruiting
Not Applicable

IH, Brain Health, and T2D

AgingType 2 Diabetes
Darren P Casey80 enrolled1 locationNCT07173543
Recruiting
Phase 1

A Study to Evaluate the Effect of RO7204239 on Insulin Sensitivity and Muscle Composition in Participants With Type 2 Diabetes Mellitus (T2DM) and Overweight or Obesity

ObesityOverweightType 2 Diabetes Mellitus
Hoffmann-La Roche30 enrolled1 locationNCT07137585
Recruiting
Not Applicable

Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabetes Mellitus

Type 2 DiabetesHalitosisPeriodontitis
University of Sao Paulo32 enrolled1 locationNCT07463859
Recruiting
Phase 1

SGLT2i, Pioglitazone, and Ketone Production in T2D

Type 2 Diabetes
The University of Texas Health Science Center at San Antonio64 enrolled1 locationNCT07053319
Recruiting
Not Applicable

Targeting Risk Factors for Diabetes in Subjects With Normal Blood Cholesterol Using Omega-3 Fatty Acids

Insulin Sensitivity/ResistanceInflammationType 2 Diabetes+1 more
Institut de Recherches Cliniques de Montreal48 enrolled1 locationNCT04485871
Recruiting
Not Applicable

Diabetes Body Project 2

Type 2 DiabetesEating Disorders
Joslin Diabetes Center42 enrolled1 locationNCT07468188
Recruiting
Not Applicable

Closed-loop in Adults With Type 2 Diabetes

Type 2 Diabetes Treated With Insulin
University of Cambridge224 enrolled12 locationsNCT06579404